On September 15, 2016 Zymeworks Inc., a biopharmaceutical company discovering and developing innovative multi-functional protein-based therapeutics, including bi-specific antibodies and drug conjugates for the treatment of cancer, reported that the first patient was dosed in a Phase 1 clinical trial of ZW25 for treatment of HER2-expressing tumors (Press release, Zymeworks, SEP 15, 2016, View Source [SID:SID1234515174]). Schedule your 30 min Free 1stOncology Demo! As Zymeworks’ lead therapeutics program, ZW25 is a novel bi-specific antibody developed using the Company’s Azymetric platform. The compound targets two different epitopes (bi-paratopic targeting) of the human epidermal growth factor receptor 2 (HER2) protein, which is over-expressed on the surface of many tumor types, including certain breast, gastric, lung, and ovarian cancers.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to have begun enrollment in this initial study of ZW25," said Diana Hausman, M.D., Zymeworks’ Chief Medical Officer. "No approved HER2-targeted therapies exist for many patients with HER2-expressing cancers and with its unique mechanism of action, ZW25 has the potential to address this significant unmet need."
ZW25 is being evaluated in the clinic for safety, as well as efficacy, in patients with tumors with low to moderate levels of HER2 expression. ZW25 is active in numerous in vivo models of HER2 low to high expressing cancers, including ovarian cancer, for which it has received Orphan Drug Designation from the FDA. ZW25 has demonstrated an acceptable safety profile in preclinical toxicology studies when administered at multiple dose levels using a once per week dosing schedule.
About ZW25
ZW25 is Zymeworks’ lead therapeutics program based on the Azymetric platform. It is an engineered bi-specific antibody that targets two different epitopes (bi-paratopic targeting) of the HER2 protein and confers its efficacy via multiple mechanisms of action, including: (i) enhanced antibody-mediated effector function resulting from the increased decoration of the tumor cell surface; (ii) increased blockade of the HER2 cellular growth signal by the dual engagement of HER2 epitopes; and (iii) increased removal of surface-expressed HER2 protein due to enhanced HER2 internalization upon antibody engagement. ZW25 is a best-in-class HER2-targeting antibody for a variety of tumors characterized by HER2 overexpression, including breast, gastric, ovarian, colorectal and non-small cell lung cancers. The FDA has granted Orphan Drug Designation to ZW25 for the treatment of ovarian cancer.